Last reviewed · How we verify
Lorazepam and fMRI
Lorazepam is a benzodiazepine that enhances GABAergic inhibitory neurotransmission in the central nervous system, and fMRI is a neuroimaging technique used to visualize brain activity changes in response to the drug.
Lorazepam is a benzodiazepine that enhances GABAergic inhibitory neurotransmission in the central nervous system, and fMRI is a neuroimaging technique used to visualize brain activity changes in response to the drug. Used for Anxiety disorders, Insomnia, Seizure disorders.
At a glance
| Generic name | Lorazepam and fMRI |
|---|---|
| Also known as | Ativan |
| Sponsor | University of Michigan |
| Drug class | Benzodiazepine |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology; Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Lorazepam binds to GABA-A receptors and potentiates the inhibitory effects of GABA, leading to anxiolytic, sedative, and anticonvulsant effects. The fMRI component allows researchers to map and measure changes in brain activation patterns and functional connectivity induced by lorazepam administration, typically used in research settings to understand drug effects on neural circuits rather than as a therapeutic mechanism itself.
Approved indications
- Anxiety disorders
- Insomnia
- Seizure disorders
- Alcohol withdrawal
Common side effects
- Sedation
- Dizziness
- Ataxia
- Dependence/tolerance
- Respiratory depression
Key clinical trials
- Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression (PHASE4)
- Exploring the Effects of Diazepam and Lorazepam (NA)
- Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis (PHASE4)
- Effects of Oxytocin and Lorazepam on Fear-related Intra-amygdalar Activity (PHASE1)
- A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise (PHASE4)
- Biological Basis of Individual Variation in Social Cooperation (NA)
- A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers (PHASE1)
- A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lorazepam and fMRI CI brief — competitive landscape report
- Lorazepam and fMRI updates RSS · CI watch RSS
- University of Michigan portfolio CI